AU2004210753A1 - Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent - Google Patents
Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent Download PDFInfo
- Publication number
- AU2004210753A1 AU2004210753A1 AU2004210753A AU2004210753A AU2004210753A1 AU 2004210753 A1 AU2004210753 A1 AU 2004210753A1 AU 2004210753 A AU2004210753 A AU 2004210753A AU 2004210753 A AU2004210753 A AU 2004210753A AU 2004210753 A1 AU2004210753 A1 AU 2004210753A1
- Authority
- AU
- Australia
- Prior art keywords
- amido
- formula
- products
- methylquinolinio
- pyridinedicarboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0301478A FR2850970B1 (fr) | 2003-02-07 | 2003-02-07 | Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique |
| FR03/01478 | 2003-02-07 | ||
| PCT/FR2004/000260 WO2004072027A2 (fr) | 2003-02-07 | 2004-02-05 | Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004210753A1 true AU2004210753A1 (en) | 2004-08-26 |
Family
ID=32731875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004210753A Abandoned AU2004210753A1 (en) | 2003-02-07 | 2004-02-05 | Chemical derivatives binding very specifically with G-quadruplex DNA structures and use thereof as a specific anti-cancer agent |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1603898A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006518726A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004210753A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0407320A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2514105A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2850970B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05007648A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004072027A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887873B2 (en) | 2001-03-23 | 2005-05-03 | Aventis Pharma S.A. | Triazine derivatives and their application as antitelomerase agents |
| US8293716B2 (en) | 2005-05-26 | 2012-10-23 | Ramot At Tel Aviv University Ltd. | Method of treating cancer by modulation of mortalin |
| EP2061464A2 (en) * | 2006-09-14 | 2009-05-27 | Ramot, at Tel Aviv University Ltd. | Combination therapy for tumoral disease treatment |
| GB0706932D0 (en) * | 2007-04-10 | 2007-05-16 | Univ London Pharmacy | Ureylene derivatives |
| WO2009040819A2 (en) | 2007-09-25 | 2009-04-02 | Ramot At Tel Aviv University Ltd. | DOWN-REGULATION OF MORTALIN BY siRNA |
| JP4410844B1 (ja) | 2008-05-27 | 2010-02-03 | パナソニック株式会社 | G−quadruplex検出方法、G−quadruplex形成DNA検出方法およびテロメラーゼ活性測定方法 |
| JP4510929B1 (ja) | 2009-04-09 | 2010-07-28 | パナソニック株式会社 | テロメラーゼ反応阻害方法およびそれに用いられるテロメラーゼ反応阻害剤 |
| CN108066340B (zh) * | 2016-11-10 | 2020-10-27 | 中国科学院化学研究所 | 药物组合物 |
| CN108066341B (zh) * | 2016-11-10 | 2020-10-30 | 中国科学院化学研究所 | 化合物在制备抗癌药物中的用途 |
| WO2018211148A1 (en) * | 2017-05-19 | 2018-11-22 | Universite De Bretagne Occidentale | Bisquinolium derivatives for preventing or treating ebv-related cancers |
| CN113272294A (zh) * | 2018-08-24 | 2021-08-17 | 雅典学院生物医学研究基金会 | 2,6-双(((1h-苯并[d]咪唑-2-基)硫)甲基)吡啶和n2,n6-二苄基吡啶-2,6-二甲酰胺衍生物以及相关化合物作为磷酸肌醇3-激酶(pi3k)抑制剂用于治疗癌症 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149402A0 (en) * | 1999-11-29 | 2002-11-10 | Aventis Pharma Sa | Arylamine derivatives and their use as anti-telomerase agent |
| FR2819255B1 (fr) * | 2001-01-09 | 2003-02-28 | Aventis Pharma Sa | Derives chimiques et leur application comme agent antitelomerase |
| FR2821355A1 (fr) * | 2001-02-23 | 2002-08-30 | Aventis Pharma Sa | Derives chimiques et leur application comme agent antitelomerase |
| CO5380035A1 (es) * | 2001-03-23 | 2004-03-31 | Aventis Pharma Sa | Derivados quimicos y su aplicacion como agente antitelomerasa |
| AU2002314252A1 (en) * | 2001-05-28 | 2002-12-09 | Aventis Pharma S.A. | Chemical derivatives and the use thereof as an anti-telomerase agent |
-
2003
- 2003-02-07 FR FR0301478A patent/FR2850970B1/fr not_active Expired - Fee Related
-
2004
- 2004-02-05 WO PCT/FR2004/000260 patent/WO2004072027A2/fr not_active Ceased
- 2004-02-05 MX MXPA05007648A patent/MXPA05007648A/es not_active Application Discontinuation
- 2004-02-05 BR BRPI0407320-7A patent/BRPI0407320A/pt not_active IP Right Cessation
- 2004-02-05 JP JP2006502131A patent/JP2006518726A/ja active Pending
- 2004-02-05 EP EP04708378A patent/EP1603898A2/fr not_active Withdrawn
- 2004-02-05 AU AU2004210753A patent/AU2004210753A1/en not_active Abandoned
- 2004-02-05 CA CA002514105A patent/CA2514105A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0407320A (pt) | 2006-02-21 |
| FR2850970B1 (fr) | 2006-07-07 |
| EP1603898A2 (fr) | 2005-12-14 |
| MXPA05007648A (es) | 2006-12-15 |
| WO2004072027A3 (fr) | 2004-09-23 |
| WO2004072027A2 (fr) | 2004-08-26 |
| JP2006518726A (ja) | 2006-08-17 |
| CA2514105A1 (fr) | 2004-08-26 |
| FR2850970A1 (fr) | 2004-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eissa et al. | Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors | |
| US6995175B2 (en) | Chemical derivatives and their application as antitelomerase agent | |
| US20090226411A1 (en) | Chemical derivatives and their application as antitelomerase agents | |
| Liao et al. | 12-N-Methylated 5, 6-dihydrobenzo [c] acridine derivatives: A new class of highly selective ligands for c-myc G-quadruplex DNA | |
| JP2003515604A (ja) | アリールアミン誘導体およびそれらの抗−テロメラーゼ剤としての使用 | |
| CA2729745A1 (en) | Oxindole compounds | |
| EP2523938A1 (en) | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 | |
| EP2881397B1 (en) | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | |
| AU2016228634A1 (en) | Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof | |
| US20230219895A1 (en) | Oxynitidine derivatives useful as inhibitors of topoisomerase ib (top1) and tyrosyl-dna phosphodiesterase 1 (tdp1) | |
| JP2006518726A (ja) | G四重鎖dna構造に極めて特異的に結合する化学誘導体、および、特異的な抗ガン剤としてのそれらの使用 | |
| AU2002251140B2 (en) | Chemical derivatives and their use as anti-telomerase agent | |
| US20070232572A1 (en) | Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent | |
| US7179816B2 (en) | Chemical derivatives and their application as antitelomerase agents | |
| Wu et al. | Disubstituted 2-phenyl-benzopyranopyrimidine derivatives as a new type of highly selective ligands for telomeric G-quadruplex DNA | |
| CN111072640A (zh) | 喹唑啉类衍生物及其制备方法和应用 | |
| EP3632912B1 (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| US11065251B2 (en) | PAK1 inhibitors and uses thereof | |
| AU2002229859B2 (en) | Chemical derivatives and their use as anti-telomerase agent | |
| WO2008126123A2 (en) | Water-soluble coronene derivatives active as inhibitors of telomerase | |
| CN109400626B (zh) | 一种双-氟喹诺酮噁二唑脲类氟罗沙星衍生物及其制备方法和应用 | |
| WO2026105155A1 (en) | Tricyclic compound for breast and ovarian cancer treatment | |
| CN119431354A (zh) | 苯并五元杂环类衍生物及其应用 | |
| Hanh et al. | Development of G-quadruplex stabilizing compounds identified through a High-Throughput Screen | |
| WO2020023700A2 (en) | OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (Tdp1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |